Clinitech Laboratory Ltd

Clinitech Laboratory Limited has filed a statement confirming no deviation or variation in the utilization of funds raised through its Public Issue (IPO) as of March 31, 2026. The company raised ₹578.30 Lakhs on July 30, 2024. Funds were primarily allocated for the expansion of diagnostic centres (₹498.67 Lakhs), general corporate purposes (₹41.33 Lakhs), and issue-related expenses (₹38.30 Lakhs). As of the reporting quarter, ₹528.30 Lakhs has been utilized, with the company asserting full adherence to the original objects of the issue.

CLINITECH LABORATORY LIMITED's Board of Directors met on May 28, 2026, and approved the Audited Standalone & Consolidated Financial Results for the half year and financial year ended March 31, 2026. The Board also took note of the Internal Audit Report for the half year ended March 31, 2026, and related party transactions for FY26, while approving estimated related party transactions for FY2026-27. The Statutory Auditors, M/s Kale Malde & Co., issued an "unmodified opinion" on the financial results.

CLINITECH LABORATORY LIMITED's Board of Directors met on May 28, 2026, to approve the Audited Standalone & Consolidated Financial Results for the half year and financial year ended March 31, 2026. The Board also took note of the Internal Audit Report for the half year ended March 31, 2026, and reviewed related party transactions for FY 2025-26, approving estimated transactions for FY 2026-27. The Statutory Auditors, M/s Kale Malde & Co., issued an "unmodified opinion" on the financial statements. The company also enclosed a certificate regarding the utilization of issue proceeds.

Clinitech Laboratory Ltd has scheduled a Board of Directors meeting on May 28, 2026, to consider and approve the audited standalone and consolidated financial statements and financial results for the half-year and financial year ended March 31, 2026. The board will also review the internal audit report and related party transactions for the same period. The trading window has been closed from April 1, 2026, and will remain closed until 48 hours after the financial results are announced.

Clinitech Laboratory Limited has entered into a Memorandum of Understanding (MOU) dated April 25, 2026, with M/s. MD Plus Multispeciality Clinic. The MOU involves operating a pathology lab and handling a pickup point for pathology and full referral radiology services by Clinitech.

Clinitech Laboratory Ltd (CTLLAB) has filed an undertaking confirming the non-applicability of disclosure requirements under Regulation 23 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, concerning Related Party Transactions (RPT). This exemption is valid for the half-year and financial year ending March 31, 2026. The company qualifies for this exemption under Regulation 15 of SEBI (LODR) Regulations, 2015, as it is listed on the SME portal of BSE Limited and does not exceed the specified threshold limits for RPT disclosures.

Clinitech Laboratory Ltd has announced a change in its market maker from SVCM Securities Private Limited to Kalpalabdhi Financials Private Limited, effective from April 10, 2026. This change is due to the discontinuation of the existing market maker, SVCM Securities Private Limited, as a result of its internal restructuring. A tripartite agreement has been executed between the company, Inventure Merchant Banker Services Private Limited (Lead Manager), and Kalpalabdhi Financials Private Limited (Market Maker). The necessary applications to SEBI and the stock exchange will be made within the prescribed time limit to update/intimate the change in market maker.

Clinitech Laboratory Ltd has received a yearly disclosure under regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeover) Regulation, 2011, as amended, from the Promoter & Promoters Group of the Company for the year ended on 31st March, 2026. The promoter, Mr. Jagdish Nayak, held 7,22,500 equity shares of the Company as on March 31, 2026. However, he acquired an additional 9,600 equity shares on March 30, 2026, which were reflected in the BENPOS on April 1, 2026. The company confirms that no encumbrance was made over the shares held by them directly or indirectly during the financial year ended March 31, 2026. All requisite disclosures have been filed with the relevant authorities within the prescribed time limit.

Jagdish Umakant Nayak, a promoter of Clinitech Laboratory Limited, has acquired 9,600 equity shares of the company on March 30, 2026. This acquisition is in compliance with Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The total share capital of the company remains unchanged at 22,82,400 equity shares after the acquisition.

Siddhesh Anant Nayak, a promoter of Clinitech Laboratory Ltd, has acquired 2,400 equity shares of the company under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. This acquisition was made on March 27, 2026, through the open market. The total share capital of the company remains the same before and after the acquisition.